Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141542 · ClinicalTrials.gov registry record · Phase 1
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
A Phase 1 study of Metastatic Melanoma, sponsored by F. Stephen Hodi, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT02141542: Completed Phase 1 study of Metastatic Melanoma, sponsored by F. Stephen Hodi, MD.
NCT02141542 is a Phase 1 study of Metastatic Melanoma that has completed, run by F. Stephen Hodi, MD. The registered enrollment target is 15 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02141542, a Phase 1 study of Metastatic Melanoma, has completed, sponsored by F. Stephen Hodi, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.
Primary Outcome
Determination of the maximum tolerated dose (MTD) of the combination of tremelimumab and MEDI3617
Conditions Studied
Interventions
- DRUG Tremelimumab
- DRUG MEDI3617
Study Locations (2)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-05 |
| Est. Completion | 2020-09-23 |
| Phase | Phase 1 |
What the finished NCT02141542 record still lists
NCT02141542 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Tremelimumab is the first listed.
NCT02141542 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02141542 about?
NCT02141542 is a clinical study titled "Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma". This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.
What is the current status of trial NCT02141542?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-05. Estimated completion is 2020-09-23.
What conditions does trial NCT02141542 study?
This clinical trial studies the following conditions: Metastatic Melanoma.
What interventions are being tested in trial NCT02141542?
The interventions under investigation include: Tremelimumab (DRUG), MEDI3617 (DRUG).
Who is sponsoring clinical trial NCT02141542?
This trial is sponsored by F. Stephen Hodi, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141542 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02141542's enrollment target sits among peer trials
15 79th of 91 higher than 10 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia